Goldman Sachs JB Were this am lifted rating to short term 'outperform' and put a valuation of $6.71 on stock.At $5.84 looks like it still has a good rise ahead.
ACW This biotech stock raised $11M in a risk-off environment. Its Alzheimer's drug could change the game
History-making uranium sample grades and an imminent drill run. Infini Resources is poised to transform in 2025